Lennox-Gastaut%2525252525252525252525252525252525252520syndrome

# Lennox-Gastaut Syndrome (LGS) ## Overview Lennox-Gastaut Syndrome is a severe form of childhood-onset epilepsy characterized by multiple seizure types, slow spike-and-wave EEG patterns, and cognitive impairment. Pharmacotherapy is typically adjunctive, as monotherapy is rarely effective. ## Primary Indications Treatment of seizures associated with LGS. Common FDA-approved agents include: * **Rufinamide** * **Clobazam** * **Topiramate** * **Lamotrigine** * **Cannabidiol** * **Felbamate** (Third-line due to toxicity) ## Adult Dosing * **Rufinamide:** Start 400–800 mg/day in two divided doses; titrate by 400–800 mg every 2 days to max 3200 mg/day. * **Clobazam:** 10–20 mg/day; may titrate up to 40 mg/day. * **Cannabidiol:** 10 mg/kg/day; increase to 20 mg/kg/day as tolerated. * **Topiramate:** 200–400 mg/day in two divided doses. * **Lamotrigine:** 200–400 mg/day. ## Pediatric Dosing * **Rufinamide (≥1 year):** Start 10 mg/kg/day; titrate by 10 mg/kg increments every 2 days to max 45 mg/kg/day (not to exceed 3200 mg/day). * **Clobazam (≥2 years):** Weight-based dosing: ≤30 kg start 5 mg/day (titrate to 20 mg/day); >30 kg start 10 mg/day (titrate to 40 mg/day). * **Cannabidiol (≥1 year):** Start 2.5 mg/kg twice daily (5 mg/kg/day); increase to 10 mg/kg twice daily (20 mg/kg/day) after 1 week. * **Topiramate (≥2 years):** 5–9 mg/kg/day in two divided doses. * **Lamotrigine (≥2 years):** Dosing varies significantly by concurrent AED use (especially valproic acid). Must follow slow titration schedules to prevent rash. ## Dose Adjustments * **Renal:** Dose reduction required for most agents; follow specific product labeling for CrCl <30–50 mL/min. * **Hepatic:** Reduce doses for valproate, topiramate, and clobazam in presence of hepatic impairment. * **Drug Interactions:** Dose adjustments are mandatory when adding/removing enzyme-inducing (phenytoin, carbamazepine) or enzyme-inhibiting (valproate) AEDs. ## Contraindications * **Rufinamide:** Familial Short QT syndrome (shortens the QT interval). * **Felbamate:** Known history of aplastic anemia or hepatic failure. * **General:** Hypersensitivity to active ingredients or excipients. ## Adverse Effects * **General:** Somnolence, dizziness, fatigue, ataxia, irritability, and cognitive impairment. * **Specific:** * **Rufinamide:** Shortened QT interval (ECG monitoring required). * **Topiramate:** Parasthesia, metabolic acidosis, nephrolithiasis, hypohidrosis. * **Cannabidiol:** Elevated transaminases (ALT/AST), diarrhea, anorexia. * **Felbamate:** Aplastic anemia and hepatic failure (requires hematologic/hepatic monitoring). ## Key Drug Interactions * **Valproate:** Significantly increases serum levels of Lamotrigine and Clobazam (active metabolite). * **Enzyme Inducers (CBZ/PHT/PB):** Decrease levels of Rufinamide, Topiramate, and Clobazam. * **Cannabidiol:** Can increase levels of clobazam's active metabolite (N-desmethylclobazam), increasing risk of sedation. ## Monitoring * **Baseline:** CBC, LFTs, ECG (especially for Rufinamide). * **Ongoing:** Seizure frequency/type logs, serum concentrations (where applicable), weight, and developmental milestones. * **Specific:** Monitor ALT/AST with Cannabidiol; monitor serum HCO3 for metabolic acidosis with Topiramate. ## Clinical Pearls * **Titration:** Most LGS medications require slow titration to minimize CNS side effects. * **Polypharmacy:** LGS treatment is almost universally polytherapeutic. Due to complex PK/PD interactions, use titration calculators and monitor for toxicity when changing regimens. * **Refractory:** If standard adjunctive therapy fails, consider high-fat, low-carbohydrate diets (e.g., Ketogenic Diet) or Vagus Nerve Stimulation (VNS). *** **Educational Disclaimer:** This information is for educational purposes only. Dosing protocols must be verified against current institutional guidelines and the most recent FDA/EMA prescribing information. Always consult package inserts and professional clinical decision support tools before prescribing.